Biosimilar Inspection Modernization Act of 2025
- Bill Number
- S. 3510
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-12-16: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2026-01-12T16:41:05Z
AI-Generated Summary
Purpose
The Biosimilar Inspection Modernization Act of 2025 aims to enhance the Food and Drug Administration's (FDA) inspection processes for facilities that manufacture, prepare, propagate, or process biosimilar biological products. Biosimilars are lower-cost versions of approved biologic drugs (like vaccines or proteins) that are highly similar and interchangeable with their reference products. The legislation seeks to make inspections more efficient, risk-based, and flexible, including through international agreements and modern tools, to ensure safety while supporting faster market access.
Key Provisions
- Definitions (Section 2): Defines key terms, including "biosimilar biological product" (a product licensed under section 351(k) of the Public Health Service Act), "biosimilar biological product establishment" (a registered facility involved in producing such products), and "Secretary" (the Secretary of Health and Human Services, acting through the FDA Commissioner).
- Public Meeting and Report on Mutual Recognition Agreements (Section 3): Requires the FDA to hold a public meeting within 180 days of enactment to discuss mutual recognition agreements (MRAs)—international pacts where the U.S. accepts inspections from trusted foreign regulators. The meeting covers current MRA use for biosimilar inspections, improvement areas, and expansions (e.g., remote assessments or virtual expert interactions). Within another 180 days, the FDA must submit a report with recommendations to congressional committees and make it public.
- Flexibility in Inspection Tools (Section 4): Mandates FDA updates to inspection processes to adopt a risk-based approach (prioritizing higher-risk facilities). This includes increasing remote regulatory assessments (virtual reviews guided by FDA's June 2025 Q&A document or successor) and maximizing alternative tools like data reviews or video inspections to boost efficiency.
- Strategic Plan for Domestic Inspections (Section 5): Requires the FDA to develop and publish, within one year of enactment, a plan addressing domestic biosimilar facility inspection challenges. It covers recruiting/retaining inspectors, unique domestic issues, improving internal FDA communication, and enhancing external communication with biosimilar application sponsors (e.g., early notifications about inspections).
Significant Changes to Existing Law
This bill builds on existing FDA authorities under the Federal Food, Drug, and Cosmetic Act (for inspections) and the Public Health Service Act (for biosimilar approvals) without fundamentally altering them. Key additions include:
- Mandating a public meeting, report, process updates, and strategic plan—none of which were previously required specifically for biosimilars.
- Emphasizing expanded use of MRAs and remote tools, which promotes modernization but does not create new enforcement powers; it directs the FDA to leverage and improve current guidance on remote assessments.
Potential Impacts
- Government Agencies: The FDA will face increased administrative burdens (e.g., meetings, reports, planning) but could gain efficiency through risk-based and remote inspections, potentially reducing travel costs and backlog. Congressional oversight via reports strengthens accountability.
- Citizens: Improved inspections may enhance the safety and quality of biosimilars, leading to more affordable treatments for conditions like cancer or autoimmune diseases. Faster processes could accelerate biosimilar approvals, benefiting patients reliant on biologics.
- International Relations: By promoting MRAs and trusted foreign inspections, the bill could foster stronger regulatory partnerships (e.g., with Europe or other allies), streamlining global supply chains for biosimilars and reducing duplicative efforts, though it does not mandate new treaties.
Main Stakeholders Affected
- FDA and HHS: Primary implementers, responsible for meetings, updates, and planning.
- Biosimilar Manufacturers and Sponsors: Facilities and companies applying for biosimilar approvals will benefit from clearer communication, flexible inspections, and potentially fewer disruptions.
- Patients and Healthcare Providers: Indirectly affected through safer, more accessible biosimilars.
- Congressional Committees: The Senate Committee on Health, Education, Labor, and Pensions and House Committee on Energy and Commerce receive reports for oversight.
- International Regulators: Foreign partners in MRAs gain opportunities for expanded collaboration.
Notable Legal, Constitutional, or Political Implications
- Legal: Reinforces FDA's existing inspection authority without expanding it, ensuring compliance with administrative law by requiring public input and transparent reporting. No challenges to due process or property rights are evident.
- Constitutional: Aligns with Congress's commerce clause powers to regulate drugs and interstate trade; promotes executive flexibility in enforcement without infringing on separation of powers.
- Political: Bipartisan (introduced by Sens. Budd and Hassan), it signals support for biosimilar innovation to lower drug costs amid ongoing debates on healthcare affordability. Could influence future FDA funding or international trade policies, but lacks controversial elements like new mandates on private entities.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Sen. Hassan, Margaret Wood [D-NH]
Recent Actions
- 2025-12-16: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-12-16: Introduced in Senate
Bill Versions
- Biosimilar Inspection Modernization Act of 2025 — issued 2025-12-16 — PDF (5 pages)